Member Info for Peelweight

Happy New Year all Syners!

Hoping for an improved 2023

Peel

Sure Doc, agreed

DocDaneeka, I think the list is a very professional assessment of the world literature and each item that is "recommended against" has an alpha-numeric code after it (latin numerals) which signify the level of evidence for the statement. It is useful for clinicians as they are being told they would be found to have treated a patient incorrectly if they gave anything on the list without that treatment being in a clinical trial. Very interesting that one could give inhaled interferon Beta to a hospitalised COVID-19 patient out with a clinical trial and not fall foul of the guidance. I am pleasantly surprised.

Interesting that inhailed interferon Beta is NOT recommended against in the hospitalised setting. Thanks titania

A P3 protocol without going up against SOC (with dynamic SOC during P3) would not get approval from an ethics committee. Particularly for a new disease with rapidly developing treatments.
Therefore there was no error in the protocol, in my opinion

Hi OB, Averaging down and long hold planned! Faith kept but significant delay now expected

Reference

https://www.nature.com/articles/d41586-021-01827-w

Re Casanova, hope this helps,

Jean-Laurent Casanova, a geneticist at the Rockefeller University in New York City. He co-leads a consortium called the COVID Human Genetic Effort, which in September 2020 reported7 spotting mutations in people with severe COVID-19 that disable genes involved in a potent antiviral response, called type 1 interferon immunity. (One of the genes in which they found mutations, IFNAR2, which codes for a subunit of an interferon receptor, has also been flagged by multiple GWAS.) The mutations identified by Casanova’s team were rare, but in a follow-up study8, the researchers found that 10% of people with life-threatening COVID-19 produced antibodies that inactivate type 1 interferons — mimicking the effects of the gene mutations. Casanova says his team looked for them only after they identified the genetic mutations, underscoring the power of his approach to point to new lines of research. “Essentially what we’ve cracked is a mechanism of critical COVID-19 pneumonia,” he says.

Thanks for the roundup Wigster77 and Doc83, very much appreciated. I am encouraged to hear they hope to land on one or more platform trial(s). Likely to be the most productive way forward and certainly best for keeping down cash-burn.

Thanks for the link WelshFalcon

I wish it were possible but it would not make sense sadly as SOC has been improved by the addition of Dex since P2. It would not make scientific sense to merge them sadly, wish it did!

For me, the mention of a platform trial is not for nothing. The US ACTIV3 trial will look at our safety data (excellent again) and risk of death data, encouraging but not statistically significant - possibly as not genuinely true, or possibly as trial too small to show. I believe this data will indicate it is a sensible candidate drug to trial. The massive benefit of the ACTIV3 programme is that it is free to the Pharma company. COVID still killing many Americans daily. Just my thoughts.

Pj, all the phases of Activ2 are done at home. Dexamethasone is not given at home. Even SNG themselves have not seen the A2P2 data yet, which is why RM said in the RNS today that we await A2P2 and A2P3 data for at home use

Ndn, Beforegolf could be described in many, many positive ways. bluffer is not one of them.

Come on Eve, we need a gold!

And of course positive SNG RNS on Monday, in case anyone thinks I'm straying off topic after a pile of booze

Hi Manifesto, good effort calling yourself out! I’m glad you’re sleuthing on this and like you, expect another TR1 fairly soon

Damn straight

Good positive sentiment after a tough week of SP. Holding for the big RNS for sure

Elsol, I will confess I don’t need an alarm clock any more. Always wake at 6-something. 7.02, it’s a date!

Ndn,
he agonised